Intimation of Outcome of Board Meeting for Recommending Final Dividend.
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts more than Nifty Midcap 150 and 2.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Global Health Ltd (Medanta) reported FY26 consolidated revenue of Rs 44,102.66 million, up 19.4% from Rs 36,923.45 million in FY25. Profit after tax grew 15.1% to Rs 5,540.68 million from Rs 4,813.18 million. Basic EPS improved to Rs 20.71 from Rs 17.92. The Board recommended a final dividend of Rs 0.50 per share (25% on face value of Rs 2), subject to shareholder approval at AGM. Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion with no qualifications. Exceptional items of Rs 10.21 million net include impact of new labour codes (Rs 365.98 million charge), partially offset by reversal of EPCG interest liability (Rs 195.92 million) and stamp duty reversal (Rs 159.85 million).
The company delivered strong double-digit revenue and PAT growth with an unmodified auditor opinion, signalling financial health. The dividend recommendation reinforces confidence in cash generation. Revenue growth near the 20% threshold could attract growth-focused investors.